Neurocrine Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBIX research report →
About the company
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
- CEO
- Kyle W. Gano
- IPO
- 1996
- Employees
- 1,800
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $17.52B
- P/E
- 25.97
- P/S
- 5.65
- P/B
- 5.14
- EV/EBITDA
- 18.48
- Div Yield
- 0.00%
- Gross Margin
- 98.17%
- Op Margin
- 25.19%
- Net Margin
- 21.55%
- ROE
- 21.64%
- ROIC
- 13.68%
- Revenue
- $2.86B · 21.45%
- Net Income
- $478.60M · 40.23%
- EPS
- $4.81 · 41.47%
- Op Income
- $619.10M
- FCF YoY
- 34.37%
- 52W High
- $174.38
- 52W Low
- $122.14
- 50D MA
- $154.14
- 200D MA
- $142.42
- Beta
- 0.39
- Avg Volume
- 1.24M
Get TickerSpark's AI analysis on NBIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Lippoldt Darin | other | 8,110 |
| Jun 29, 26 | Lippoldt Darin | other | 1,690 |
| Jun 26, 26 | Lippoldt Darin | other | 200 |
| Jun 29, 26 | Lippoldt Darin | sell | 8,110 |
| Jun 26, 26 | Lippoldt Darin | sell | 200 |
| Jun 29, 26 | Lippoldt Darin | sell | 1,690 |
| Jun 26, 26 | Lippoldt Darin | other | 200 |
| Jun 29, 26 | Lippoldt Darin | other | 8,110 |
| Jun 29, 26 | Lippoldt Darin | other | 1,690 |
| Jun 5, 26 | SHERWIN STEPHEN A | other | 10,000 |
Our NBIX coverage
Recent articles, reports, and earnings notes.
No research on NBIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBIX report →Similar companies
Peers in the same neighborhood.